Back Hepatitis C

Hepatitis C

Study Sheds Light on How Hepatitis C Virus Evades Immune System

Hepatitis C virus (HCV) appears to disable a specific variant of the IFNL3 gene, which plays a role in the immune system's response against viral infection, explaining how people with a favorable gene pattern are more likely to clear the virus naturally or with interferon-based treatment, researchers reported in the January 2014 issue of Nature Immunology.

alt

Sofosbuvir/Ledipasvir Coformulation Cures 95% of Genotype 1 Hepatitis C

Between 95% and 100% of treatment-naive patients and prior non-responders with genotype 1 chronic hepatitis C achieved sustained virological response using a fixed-dose combination of sofosbuvir plus ledipasvir, with or without ribavirin, according to findings from the Phase 2 LONESTAR study published in the February 8, 2014, edition of The Lancet.

alt

AASLD, IDSA & IAS-USA Announce New Hepatitis C Treatment Guidelines

The American Association for the Study of Liver Diseases (AASLD), the Infectious Diseases Society of America (IDSA), and the International Antiviral Society-USA (IAS-USA) this week announced the first new hepatitis C treatment guidelines that include next-generation direct-acting antiviral agents recently approved by the FDA. The guidance is available on a new website, HCVguidelines.org, that will enable frequent updates to reflect emerging data.

alt

Gilead Requests FDA Approval of Sofosbuvir/ Ledipasvir Hep C Combo

Gilead Sciences announced this week that it has filed for U.S. Food and Drug Administration (FDA) approval of a new fixed-dose coformulation containing its recently approved HCV polymerase inhibitor sofosbuvir (Sovaldi, formerly GS-7977) plus its NS5A inhibitor ledipasvir (formerly GS-5885) for interferon-free treatment of genotype 1 chronic hepatitis C.

alt

Daclatasvir + Asunaprevir + BMS-791325 Cures Most Genotype 1 Hepatitis C

An interferon-free oral combination of 3 direct-acting antiviral agents developed by Bristol-Myers Squibb led to sustained virological response in more than 90% of treatment-naive chronic hepatitis C patients with HCV genotype 1a or 1b, according to a report in the February 2014 issue of Gastroenterology.

alt

Hepatitis C May Increase Risk of Strokes

Hepatitis C virus (HCV) infection significantly increases the likelihood of having a stroke, but further information is needed to understand underlying mechanisms and identify related risk factors such as HCV genotype, according to a meta-analysis described in the November 12, 2013, edition of PLoS ONE.

alt

Boehringer Ingelheim Halts Testing of Deleobuvir Hepatitis C Regimens

Boehringer Ingelheim will cease development of regimens containing its non-nucleoside hepatitis C virus polymerase inhibitor deleobuvir (formerly BI 207127), the company announced this week.

alt

AbbVie Oral Regimen Cures Nearly All GT1 Hepatitis C, Phase 3 Trials Now Done

AbbVie announced this week that it has completed Phase 3 clinical trials of its interferon-free regimen containing 3 direct-acting antivirals, with or without ribavirin, for the treatment of chronic hepatitis C. Across all studies, between 90% and 100% of participants achieved sustained virological response, usually with 12 weeks of therapy, including hard-to-treat patient groups such as people with HCV subtype 1a and liver cirrhosis.

alt

Samatasvir + Simeprevir for Hepatitis C Shows High Early Cure Rate

An interferon-free regimen containing Idenix Pharmaceuticals' hepatitis C virus NS5A inhibitor samatasvir (formerly IDX719) plus the recently approved HCV protease inhibitor simeprevir (Olysio) and ribavirin demonstrated an 85% sustained response rate at 4 weeks post-treatment in the Phase 2 HELIX-1 trial, according to a company announcement.

alt